Table II.
Univariate analyses of the clinical characteristics for PFS and OS.
| 2-year PFS | 2-year OS | |||||
|---|---|---|---|---|---|---|
| Characteristics | RR | 95% CI | P-value | RR | 95% CI | P-value |
| Sex | ||||||
| Male | 1 | 1 | ||||
| Female | 0.418 | 0.170–1.028 | 0.057 | 0.274 | 0.090–0.835 | 0.061 |
| Age (years) | ||||||
| ≤60 | 1 | 1 | ||||
| >60 | 0.544 | 0.228–1.300 | 0.171 | 0.439 | 0.163–1.180 | 0.103 |
| B symptoms | ||||||
| Yes | 1 | 1 | ||||
| No | 0.513 | 0.214–1.227 | 0.134 | 0.410 | 0.159–1.062 | 0.066 |
| Ann Arbor stage | ||||||
| I+II | 1 | 1 | ||||
| III+IV | 2.754 | 1.013–7.485 | 0.047a | 1.927 | 0.686–5.414 | 0.213 |
| IPI score | ||||||
| ≤2 | 1 | 1 | ||||
| >2 | 2.501 | 1.076–5.816 | 0.033a | 2.381 | 0.943–6.012 | 0.066 |
| LDH level | ||||||
| Normal | 1 | 1 | ||||
| Abnormal | 5.926 | 1.986–17.680 | 0.001a | 4.495 | 1.469–13.758 | 0.008a |
| β2-MG | ||||||
| Normal | 1 | 1 | ||||
| Abnormal | 1.252 | 0.535–2.930 | 0.605 | 1.469 | 0.579–3.726 | 0.418 |
| Nln | ||||||
| <2 | 1 | 1 | ||||
| ≥2 | 2.139 | 0.723–6.327 | 0.170 | 2.381 | 0.686–8.256 | 0.172 |
| Neo | ||||||
| <2 | 1 | 1 | ||||
| ≥2 | 2.124 | 0.886–5.092 | 0.091 | 2.202 | 0.850–5.703 | 0.104 |
| BMI | ||||||
| No | 1 | 1 | ||||
| Yes | 1.307 | 0.442–3.868 | 0.629 | 0.977 | 0.280–3.401 | 0.970 |
| Necrosis | ||||||
| No | 1 | 1 | ||||
| Yes | 3.594 | 1.526–8.465 | 0.003a | 4.085 | 1.612–10.356 | 0.003a |
a
Statistically significant. PFS, progression-free survival; OS, overall survival; RR, relative risk; CI, confidence interval; IPI, International Prognostic Index; LDH, lactate dehydrogenase; β2-MG, β2 microglobulin; Nln, number of lymph node area involvement; Neo, number of extranodal organ involvement; BMI, bone marrow involvement.